Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


6th World Congress and Expo on Applied Microbiology

Rome, Italy

Hiroshi Ohrui

Hiroshi Ohrui

Yokohama University of Pharmacy, Japan

Title: EFdA: An extremely excellent anti-HIV nucleoside from design to the current clinical trial results


Biography: Hiroshi Ohrui


EFdA (4’-C-ethynyl-2-fluoro-2’-deoxyadenosine) prevents the emergence of resistant HIV mutants, is over 400 times more active than AZT and several orders of magnitude more active than other clinical reverse-transcriptase inhibitory 2’, 3’-dideoxynucleoside drugs, very low toxic, very long acting, and very useful for prophylaxis. EFdA is now under clinical investigation by Merck & Co. as MK-8591. In the beginning, a general idea for the development of anti-viral modified nucleosides is presented. Next, the development of EFdA is discussed and then the current clinical trial results by Merck will be presented. For the development of EFdA, four working hypotheses, the way to prevent the emergence of resistant HIV mutants, the way to decrease the toxicity of nucleosides, the way to provide nucleoside with stability for long acting, the difference of the substrate selectivity between human and viral nucleic acid polymerases makes it possible to develop very excellent anti-viral modified nucleosides, were proposed. 4’-C-substituted-2’-deoxy nucleoside (4’SdN) was designed as the nucleoside which could satisfy these hypotheses. The study on 4’SdN has successfully resulted in the development of EFdA.